[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:esophageal-adenocarcinoma:msi1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Esophageal Adenocarcinoma","MSI1 Gene",5,[8,16,23,30,37],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06203600","Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial",[12],"Phase 2\u002FPhase 3","RECRUITING","2026-08-26T02:17:28.381459Z","2026-05-05T02:43:28.966545Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06824363","ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w\u002FARID1a Mu",[20],"Early Phase 1","2026-08-26T02:15:17.167444Z","2026-05-05T02:43:26.849550Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT03539822","Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies",[27],"Phase 1\u002FPhase 2","2026-08-26T02:18:58.141497Z","2026-05-05T02:43:26.745155Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT07290985","AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas",[34],"Phase 2","2026-08-26T02:17:07.954622Z","2026-07-24T01:27:14.911516Z",{"nct_id":38,"title":39,"phases":40,"status":42,"updated_at":43,"content_modified":44},"NCT07594548","Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma",[41],"Phase 1","NOT_YET_RECRUITING","2026-08-26T02:17:36.611194Z","2026-05-29T15:36:40.205969Z"]